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BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide. As the sensitivity and specificity of current diagnostic
markers are not perfect, we examined whether ubiquitin-like with PHD and ring finger domains 1 (UHRF1), which is overexpressed
in various cancers but not yet examined in lung cancer in large scale, can be a novel diagnostic marker of lung cancer.
METHODS: Immunohistochemical analysis using surgical specimens obtained from 56 US and 322 Japanese patients with lung cancer
was performed.
RESULTS: The UHRF1 was stained specifically in the nuclei of cancer cells, but not in the other cells. The UHRF1 expression was
observed in all histological types of lung cancer, especially in non-adenocarcinomas (non-ADCs), both in the US and Japanese cases.
In 322 Japanese non-small cell lung cancer (NSCLC) cases, UHRF1 expression was associated with the histological type (higher
in non-ADCs; Po0.00001), gender (higher in male; P¼0.00082), smoking (higher in smokers; P¼0.00004), pT factor (higher
in advanced stage; P¼0.00010), and pN factor (higher in cancers with metastasis in regional lymph nodes; P¼0.00018). The UHRF1
expression was also associated with poor prognosis for NSCLC patients (P¼0.0364). Although UHRF1 overexpression was
associated with these malignant indicators, UHRF1 was detectable in half of lung cancer patients in an early pathological stage.
CONCLUSION: The UHRF1 is overexpressed in various types of lung cancer from early pathological stage. Therefore, detection of
UHRF1 expression in tissue specimens by immunohistochemistry can be useful for diagnosis of lung cancer in all pathological stages.
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Lung cancer is the leading cause of cancer deaths worldwide
including the United States and Japan according to the World
Health Organization (WHO) database (http://www.who.int/en/).
Among various histological types of lung cancers, non-small cell
lung cancer (NSCLC) accounts for approximately 80%, whereas
small cell lung cancer (SCLC) accounts for approximately 15%.
The two major histological types of NSCLC are adenocarcinoma
(ADC) and squamous cell carcinoma (SCC). In Japan, SCC
accounts for 34.7% and 16.3% of all lung cancer cases in males
and females, respectively. On the other hand, ADC accounts for
42.9% and 67.2% of all lung cancer cases in males and females,
respectively (incident year 1999–2003; Toyoda et al, 2008). The
remaining few per cent of NSCLC are other histological types of
carcinomas including large cell carcinoma and adenosquamous
cell carcinoma; SCC is more common in males, and smoking
dramatically increases the risk of this type of cancer; the relative
risks of smoking in males were 11.7 and 2.3 for SCC and ADC,
respectively, and were 11.3 and 1.4 correspondingly in females in
Japan (Wakai et al, 2006). Smoking rates of Japanese males and
females in 2007 are 43.3% and 12.0%, respectively, according to
Japanese exposure factors handbook published by National
Institute of Advanced Industrial Science and Technology in Japan
(http://unit.aist.go.jp/riss/crm/exposurefactors/english_summary.html).
The 5-year survival rate based on pathologic (p) stages was
analysed using a large population of Japanese lung cancer cases
(n¼13010) in 2005 (Asamura et al, 2008). According to the study,
the 5-year survival rates of SCLC patients who underwent
plumonary resections were as follows: 58.3%, 60.2%, 40.6%,
41.1%, 28.3%, 34.6%, and 30.8% for IA, IB, IIA, IIB, IIIA, IIIB,
and IV, respectively. The 5-year survival rates of NSCLC patients
who underwent plumonary resections were as follows: 83.9%,
66.3%, 61.0%, 47.4%, 32.8%, 29.6%, and 23.1% for IA, IB, IIA, IIB,
IIIA, IIIB, and IV, respectively. This study also showed that
ADC histological type, female gender, and age o50 years were
significant favourable prognostic factors.
Although there are several biomarkers in clinical use such as
SCC antigen, carcinoembryonic antigen, neuron-specific enolase,
and pro-gastrin-releasing peptide, none of them are perfect in
terms of sensitivity and/or specificity (Ando et al, 2003; Molina
et al, 2005). Thus, we have been seeking additional sensitive and
cancer-specific biomarkers detectable in serum and tumour tissues
to improve the current high mortality of lung cancer, and found
more than 20 candidate diagnostic and/or prognostic biomarkers,
which are now under development for clinical use (Daigo and
Nakamura, 2008). As many molecular signalling pathways are
disrupted during lung carcinogenesis, we believe that combi-
nations of biomarkers are necessary for precise diagnosis and
prognosis of lung cancer, and thus we continue to search for
superior biomarkers.
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sUbiquitin-like with PHD and ring finger domains 1 (UHRF1),
also known as ICBP90, was identified as a protein whose
expression is only detectable in proliferating cells, not in quiescent
cells (Hopfner et al, 2000; Unoki et al, 2004). Recently, it was
revealed that UHRF1 has a central function in epigenetic
modulation during DNA duplication in the S phase (Sharif et al,
2007; Arita et al, 2008; Avvakumov et al, 2008; Hashimoto
et al, 2008). Up-regulation of UHRF1 has been reported in
various cancers (Mousli et al, 2003; Crnogorac-Jurcevic et al, 2005;
Jenkins et al, 2005; Lorenzato et al, 2005; Oba-Shinjo et al,
2005; Pita et al, 2009; Unoki et al, 2009). As no large-scale
study of UHRF1 expression in lung cancers has been
performed, we examined whether UHRF1 could be a novel
diagnostic marker of lung cancer by immunohistochemical
analysis to understand the clinical importance of this protein in
lung carcinogenesis.
In this report, we examined UHRF1 expression using 56 US
and 322 Japanese lung cancer cases by immunohistochemical
analysis and found that expression of UHRF1 was significantly
up-regulated in almost all histological types of lung cancers,
especially in non-ADCs. The expression of UHRF1 was associated
with poor prognosis and several other clinicopathological charac-
teristics of the lung cancer patients. As UHRF1 was specifically
expressed in cancer cells and detectable in approximately half of
lung cancer cases in an early pathological stage, UHRF1 could be a
novel diagnostic marker for lung cancer.
MATERIALS AND METHODS
Lung cancer clinical tissue specimens
A total of 56 formalin-fixed primary lung cancer tissues from US
patients including SCLC and NSCLC was purchased from BioChain
Institute (Table 1; Cat T8235724-5, lot B207162; Cat T2235152,
lot A504256; Cat T2235152-9, lot A604318, Hayward, CA,
USA). A total of 322 formalin-fixed primary Japanese NSCLCs
(Table 2) and adjacent normal lung tissue samples used for
immunostaining on tissue microarrays was obtained from patients
undergoing curative surgical operation at Saitama Cancer Center
(Saitama, Japan) (Ishikawa et al, 2004, 2007). A total of 23 frozen
primary lung cancer tissues for RNA extraction was obtained as
published earlier (Kikuchi et al, 2003; Taniwaki et al, 2006). This
study as well as the use of all clinical materials described above was
approved by individual institutional Ethical Committees (Ishikawa
et al, 2004, 2007). Histological classification of tumours was
performed based on the WHO criteria. All tumours were staged
based on the pathological tumour-node-metastasis classification
of the International Union Against Cancer. Histopathological
examination of resected tumours revealed that 192 cases were
diagnosed as ADC, and the other 130 cases were classified as
non-adenocarcinoma (non-ADC).
RNA extraction and qRT–PCRs
Total RNA was extracted from frozen clinical tissues using the
TRIzol reagent (Life Technologies, Inc., Gaithersburg, MD, USA)
according to the manufacturer’s protocol. Extracted RNAs were
treated with DNase I (Nippon Gene) and reversely transcribed
using oligo(dT) primer and SuperScript II (Invitrogen, Tokyo,
Japan). For real-time TaqMan qRT–PCRs, specific primers and
probes, which strictly amplify only cDNA and not genomic DNA,
for human UHRF1 and b2-microglobulin were purchased from
Applied Biosystems (Carlsbad, CA, USA; ID: Hs00273589_m1 and
4333766F, respectively). The PCRs were performed using the ABI
Prism 7700 Sequence Detection System (Applied Biosystems)
following the manufacturer’s protocol. Amplification conditions
were 2min at 501C, 10min at 951C, and then 40 cycles each
consisting of 15s at 951C and 1min at 601C. The CT value obtained
by UHRF1 amplification was compared among the samples after
normalisation using b2-microglobulin expression levels as an
endogenous control.
Table 1 Association between the patients’ characteristics and UHRF1
expression in 56 US lung cancer cases
UHRF1 expression
High
(n¼37: 66%)
Low
(n¼19: 34%)
Total
(n¼56: 100%)
P-value
(v
2 test)
Age (years)
o65 15 (62%) 9 (38%) 24 (100%) 0.625
X65 22 (69%) 10 (31%) 32 (100%)
Gender
Female 10 (56%) 8 (44%) 18 (100%) 0.253
Male 27 (71%) 11 (29%) 38 (100%)
Histological type
ADC 6 (32%) 13 (68%) 19 (100%) 0.00009*
Non-ADC 31 (84%) 6 (16%) 37 (100%)
pT factor
T0+T1 5 (50%) 5 (50%) 10 (100%) 0.236
T2+T3 32 (70%) 14 (30%) 46 (100%)
pN factor
N0 30 (65%) 16 (35%) 46 (100%) 0.772
N1 7 (70%) 3 (30%) 10 (100%)
Abbreviations: ADC¼adenocarcinoma; non-ADC¼non-adenocarcinoma; UHRF1¼
ubiquitin-like with PHD and ring finger domains 1. *Statistically significant.
Table 2 Association between the patients’ characteristics and UHRF1
expression in 322 Japanese NSCLC cases
UHRF1 expression
High
(n¼192: 60%)
Low
(n¼130: 40%)
Total
(n¼322: 100%)
P-value
(v
2 test)
Age (years)
o65 90 (61%) 72 (49%) 148 (100%) 0.13402
X65 102 (59%) 58 (41%) 174 (100%)
Gender
Female 46 (46%) 54 (54%) 100 (100%) 0.00082*
Male 146 (66%) 76 (34%) 222 (100%)
Histological type
ADC 86 (45%) 106 (55%) 192 (100%) 4.2 10
 11**
Non-ADC 106 (82%) 24 (18%) 130 (100%)
pT factor
T1 63 (47%) 71 (53%) 134 (100%) 0.00010*
T2+T3 129 (69%) 59 (31%) 188 (100%)
pN factor
N0 107 (52%) 99 (48%) 206 (100%) 0.00018*
N1+N2 85 (73%) 31 (27%) 116 (100%)
Smoking
Never 38 (42%) 53 (58%) 91 (100%) 0.00004*
Smoking 154 (67%) 77 (33%) 231 (100%)
Abbreviations: ADC¼adenocarcinoma; non-ADC¼non-adenocarcinoma; NSCLC¼
non-small cell lung cancer; UHRF1¼ubiquitin-like with PHD and ring finger domains 1.
*Statistically significant. **Statistically most significant.
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The SBC-5 cells, whose origin was SCLC, were obtained from
Japanese Collection of Research Bioresources (Osaka, Japan).
The cell line was grown in a monolayer in Eagle’s Minimum
Essential Medium supplemented with 10% foetal bovine serum,
penicillin/streptomycin, and glutamine, at 371Ci n5 %C O 2. siRNA
oligonucleotide duplexes were purchased from SIGMA Genosys
(Sigma Aldrich Japan, Tokyo, Japan) for targeting the human
UHRF1 transcript or the EGFP and FFluc transcripts. The siRNA
targeting sequences (sense strand) are as follows: UHRF1,5 0-CUGC
UUUGCUCCCAUCAAU-30; EGFP,5 0-GCAGCACGACUUCUUCAA
GTT-30; FFluc,5 0-GUGCGCUGCUGGUGCCAACTT-30. The SBC-5
cells were transfected with EGFP siRNA, FFluc siRNA, or the
two different UHRF1 siRNAs at a final concentration of 20nM
using Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s protocol. The siRNA transfection efficiency under
the condition was 100%, as evaluated by a fluorescent siRNA (data
not shown). Then the cells were harvested after 48h of transfection
for western blotting analysis. Western blotting was performed
using anti-UHRF1 mouse monoclonal antibody (1:1000, BD
Bioscience, Tokyo, Japan) or anti-b-actin mouse monoclonal
AC-15 (Sigma Aldrich Japan).
Tissue microarray construction
Lung cancer tissue microarrays were constructed as published
earlier using formalin-fixed lung cancer tissues (Ishikawa et al, 2004;
Furukawa et al, 2005; Kato et al, 2005). Tissue areas for sampling
were selected based on visual alignment with the corresponding
haematoxylin and eosin-stained sections on slides. Three to five
tissue cores (diameter¼0.6mm; height¼3–4mm), which were
taken from donor tumour blocks, were placed into recipient
paraffin blocks using a tissue microarrayer (Beecher Instruments,
Sun Prairie, WI, USA). A core of normal tissue area was punched
from each case. A total of 5-mm sections of the resulting microarray
block were used for immunohistochemical analysis.
Immunohistochemical staining analysis
The expression patterns of UHRF1 in lung cancer and normal
human lungs were examined by immunohistochemistry as
described earlier (Unoki et al, 2004, 2009). Briefly, slides of
paraffin-embedded lung tumour specimens were processed under
high pressure (1251C, 30s) in antigen-retrieval solution with high
pH (pH 9, Dako Cytomation, Carpinteria, CA, USA), treated with
peroxidase blocking regent, and then treated with protein blocking
regent (K130, X0909, Dako Cytomation). Tissue sections were
incubated with anti-UHRF1 mouse monoclonal antibody (1:1000,
BD Bioscience), or normal mouse IgG (1:100, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) followed by HRP-conjugated
secondary antibody (Dako Cytomation). Antigen was visualised
with substrate chromogen (Dako liquid DAB chromogen;
Dako Cytomation). Finally, tissue specimens were stained with
Mayer’s haematoxylin (Muto pure chemicals Ltd., Tokyo, Japan)
for 1min to discriminate the nucleus from the cytoplasm.
Statistical analysis
A w
2 test was applied for evaluating associations between UHRF1
immunoreactivity and clinicopathological characteristics of
C
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Figure 1 Expression of UHRF1 in the US lung cancer cases detected by immunohistochemistry. (A) Specificity of the anti-UHRF1 antibody used for
immunohistochemical analysis. The SBC5 cells were transfected with EGFP siRNA, FFluc siRNA, or two independent siRNAs targeting UHRF1 mRNA. Cells
were harvested after 48h of transfection, and endogenous UHRF1 was detected by western blotting using the anti-UHRF1 antibody. b-actin was used as a
loading control. (B) Representative data of UHRF1 staining in adjacent normal lungs of US samples ( 200). (C) Representative data of UHRF1 staining in
SCLC, fibrosarcoma, and non-ADC histological types of NSCLC including SCC, large cell carcinoma, and adenosquamous carcinoma ( 200).
(D) Representative data of ADC including bronchio-alveolar carcinoma ( 200).
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spatients. Tumour-specific survival curves were calculated from the
date of surgery to the time of death related to lung cancer, or to the
last follow-up observation. The Kaplan–Meier method was applied
to generate the survival curves. Survival differences were analysed
with the log-rank test based on the status of UHRF1 expression.
This analysis was performed using StatView (version 5.0; SAS
Institute, Inc., Cary, NC, USA).
RESULTS
UHRF1 was highly expressed in the US lung cancer cases
We screened in-house cDNA microarray database (Kikuchi et al,
2003; Taniwaki et al, 2006), and found that UHRF1 mRNA was
overexpressed in 67% of NSCLCs and in 93% of SCLCs compared
with their adjacent normal lungs. To validate the microarray
data, we examined UHRF1 protein expression levels in the 56 US
lung cancer cases by immunohistochemistry with information of
age, gender, histological type, and pT and pN factors of their
cancers (Table 1). First we evaluated specificity of an anti-UHRF1
antibody by western blotting using cellular lysate from SBC5 cells
transfected with two control siRNAs and two UHRF1 siRNAs.
The result revealed that the antibody specifically recognises
endogenous UHRF1 (Figure 1A). Using the antibody, we
performed immunohistochemistric analysis. The analysis revealed
that UHRF1 was not expressed in adjacent normal lungs, stromal
cells, and invaded inflammatory cells, but was specifically
expressed in the nuclei of cancer cells (Figure 1B–D). Normal
mouse IgG served as a negative control of primary antibody in
each case, and no staining was observed (data not shown). We
scored the staining levels of UHRF1 as high or low. The UHRF1
was overexpressed in 66% of the overall NSCLCs (Table 1).
Interestingly, although expression of UHRF1 was detected in
almost all histological types of the lung cancers, its expression was
significantly higher in non-ADCs (Table 1); 84% of non-ADCs
showed high expression of UHRF1, whereas 32% of ADCs were
overexpressed UHRF1 (P¼9 10
 5, w
2 test). Other clinicopathlo-
gical factors did not show any correlation with UHRF1 expression
levels in the US samples. Importantly, UHRF1 expression was
observed in 50% of lung cancer cases in the early stage (T0þT1)
(Table 1).
Overexpression of UHRF1 was observed in Japanese lung
cancer cases and associated with histological type,
smoking, and gender
As the number of samples of the US cases was relatively small,
we analysed an additional 322 Japanese lung cancer cases with
information of postoperative clinical course, pT and pN factors
of their cancers, and smoking habit, besides information of age,
gender, and histological type (Table 2). We performed immuno-
histochemical analysis and scored the staining levels of UHRF1 as
high or low similarly to the US cases (Figure 2A). Overexpression
of UHRF1 was observed in 60% of the overall NSCLC cases
(Table 2). A w
2 test revealed that UHRF1 overexpression was
strongly associated with histological type of the Japanese cases
(higher in non-ADC; P¼4.2 10
 11). The UHRF1 high expression
was also associated with smoking (higher in smokers; P¼0.00004
by w
2 test) and gender (higher in males; P¼0.00082 by w
2 test)
(Table 2). Among these three factors, the histological type
showed the strongest correlation with overexpression of UHRF1
(P¼4.2 10
 11). We also detected UHRF1 mRNA in Japanese
cases by quantitative TaqMan PCR and found that UHRF1 mRNA
was up-regulated in the overall lung cancers, especially in non-
ADC, as the same as UHRF1 protein detected by immuno-
histochemistry (Figure 2B). At mRNA level, overexpression of
UHRF1 was observed in the overall NSCLS cases even in ADC;
UHRF1 mRNA levels were increased in 60% of ADC and in 77%
of non-ADC.
Overexpression of UHRF1 was associated with lung cancer
malignancy
Similar to the other cancers (Oba-Shinjo et al, 2005; Unoki et al,
2009), UHRF1 expression was associated with the malignant nature
of lung cancer in Japanese cases (Table 2); UHRF1 high expression
was significantly correlated with pT factor (higher in advanced
stage; P¼0.00010 by w
2 test) and pN factor (higher in cancers
with metastasis in regional lymph nodes; P¼0.00018 by w
2 test).
Although overexpression of UHRF1 associated with lung cancer
malignancy, approximately half (47%) of Japanese lung cancer
patients in T1 stage showed high expression of UHRF1 similarly to
the US cases (Table 2). Kaplan–Meier analysis revealed that the
high expression of UHRF1 was associated with poor prognosis
(P¼0.0364 by log-rank test) (Figure 2C).
DISCUSSION
Lung cancer is the most common cancer in terms of both incidence
and mortality worldwide (1.35 million new cases per year and 1.18
million deaths) according to Cancer Research UK. Survival rate
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Figure 2 Expression of UHRF1 in the Japanese lung cancer cases
detected by immunohistochemistry. (A) Representative examples of high
(positive) and low (negative) expression of UHRF1 in lung cancers and
normal lungs ( 100). (B) Expression levels of UHRF1 mRNA in Japanese
lung cancer cases were measured by TaqMan qRT–PCR. b2-microgloblin
was used for internal control. The UHRF1 mRNA was up-regulated in lung
cancers, especially in non-adenocarcinoma (non-ADC). (C) Kaplan–Meier
analysis of tumour-specific survival in lung cancer patients according to
UHRF1 expression levels. The UHRF1-high-expression group (n¼192)
showed significantly shorter survival periods compared with the
low-expression group (n¼130) (P¼0.0364: log-rank test).
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sof the cancer is still poor, partially because more than two-thirds of
lung cancers are diagnosed at a late stage. Therefore, diagnostic
markers of lung cancer, which can detect early stage lung cancer,
are required to improve the current situation. Sensitivity and/or
specificity of current diagnostic markers still need to be improved
(Ando et al, 2003; Molina et al, 2005). We have been seeking
superior diagnostic markers and identified a couple dozen of
candidates (Daigo and Nakamura, 2008). However, we are still
trying to identify other diagnostic markers to increase accuracy of
current diagnosis for responding to individual lung cancers, which
are caused by different genetic and epigenetic alterations.
The UHRF1 is significantly overexpressed in various cancers
(Mousli et al, 2003; Crnogorac-Jurcevic et al, 2005; Jenkins et al,
2005; Lorenzato et al, 2005; Oba-Shinjo et al, 2005; Pita et al, 2009;
Unoki et al, 2009). The UHRF1 transmits methylation status from
mother cells to daughter cells by recognising hemi-methylated
DNA and by recruiting DNMT1 to methylate both DNA strands
(Sharif et al, 2007; Arita et al, 2008; Avvakumov et al, 2008;
Hashimoto et al, 2008). The UHRF1 also recognises trimethyl
histone H3 lysine 9 and recruits histone modification enzymes
such as histone deacetylase 1 (HDAC1), a methyltransferase G9a,
and a histone acetylase Tip60 (Unoki et al, 2004; Karagianni et al,
2008; Achour et al, 2009; Kim et al, 2009). Thus, UHRF1 has a
central function in epigenetic transcriptional regulation. It has
been suggested that UHRF1 localises on methylated promoters of
tumour suppressor genes and suppresses expression of these genes
with transcriptional repressors such as G9a and HDAC1 (Unoki
et al, 2004; Jin et al, 2009). These results indicate that UHRF1 is
fundamentally important for cell proliferation.
In this report, we performed, for the first time, a large-scale
analysis of UHRF1 expression in lung cancer cases with clinical
information. We observed overexpression of UHRF1 in lung
cancer cases, especially in non-ADC cases, regardless of ethnic
groups, indicating that frequent overexpression of UHRF1 in non-
ADC is common worldwide. Although UHRF1 is fundamentally
important for cell proliferation, UHRF1 ‘low-expression’ popula-
tion exists. The qRT–PCR, which is more sensitive than immuno-
histochemistry, revealed that UHRF1 mRNA level was up-regulated
in approximately 70% of the overall lung cancer cases. In 30%
of the rest of lung cancers, other oncogenic pathways may be
predominantly activated. We further found that overexpression of
UHRF1 in Japanese lung cancer cases associated with gender
(higher in male) and smoking. The major histological type of
non-ADCs is SCC, which is more common in males (Toyoda et al,
2008), and smoking is the biggest risk factor for SCC (Wakai et al,
2006). In Japan, the smoking ratio for males is approximately
four-fold higher than that of females. Thus, it is reasonable that
UHRF1 overexpression associated with these three factors, the
histological type, gender, and smoking, although further analysis is
required for clarifying biological functions of UHRF1 in carcino-
genesis of non-ADCs. In the United States, prevalence of smoking
was also higher among males than females (23.9% and 18%,
respectively, in 2006) according to the Centers for Disease Control
and prevention (http://www.cdc.gov/), but the difference between
the genders in the United States is smaller than that in Japan
(1.3-fold vs 4-fold). We think that this fact reflected our result
that correlation between gender and UHRF1 expression levels in
the US cases was not significant.
Overexpression of UHRF1 also associated with cancer malig-
nancy indicated by pT and pN factors and survival rate in Japanese
cases. No correlation between UHRF1 expression and pT-pN
factors was observed in the US cases because of a lack of statistical
power. However, we would like to emphasise that overexpressed
UHRF1 was detectable in approximately half of lung cancer
patients in an early pathological stage by immunohistochemistry,
indicating that UHRF1 can be a diagnostic marker of lung cancer
even in the early stage. Combinations of UHRF1 and several other
lung cancer biomarkers including ones originally identified by our
group (Daigo and Nakamura, 2008) may yield a better outcome. In
conclusion, our data indicate that immunohistochemical staining
of UHRF1 may ameliorate the sensitivity and specificity of current
sputum examination for cancer detection, and/or to score the
malignant potential of lung cancer using biopsy/resected tissue
specimens accurately.
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